Introduction: Health economic evaluations of lung cancer screening with low-dose computed tomography (LDCT) that are underpinned by clinical outcomes are relatively few.
Introduction
Lung cancer is the leading cause of cancer-related death, both in Australia and worldwide, 1 and population-based lung cancer screening has the potential to save many lives. In 2011, a 20% (95% confidence interval [CI]: 6.8%-26.7%) relative reduction in mortality from lung cancer was observed among long-term, heavy smokers age 55 to 74 years who were screened annually for 3 years with low-dose computed tomography (LDCT) in the U.S. National Lung Screening Trial (NLST). 2 As a consequence, many organizations are now recommending annual lung screening with LDCT with variations of the NLST eligibility criteria (i.e., those aged 55-74 years with a 30-pack-year smoking history, including those who quit within the past 15 years). [3] [4] [5] [6] [7] [8] A health economic evaluation of the NLST found that LDCT screening was associated with an incremental cost-effectiveness ratio (ICER) of $52,000/life-year (LY) gained or $81,000/qualityadjusted LY (QALY) gained. 9 Many other United Statesbased cost-effectiveness analyses have reported estimates considered favorable. 10, 11 Outside the United States however, lung cancer screening has not been systematically introduced, in part because many questions remain with regard to cost-effectiveness in different settings. Further, most cost-effectiveness analyses to date have been based on preliminary assumptions regarding screening effectiveness, with exceptions including the NLST health economic evaluation. 9 These developments have prompted an urgent need for evidence on the harm, benefits, and cost-effectiveness of lung cancer screening in the Australian setting, where trial data are limited. 12 An early evaluation found that LDCT screening was likely to be cost-ineffective (approximately AU$88,000-AU$105,000/QALY). 13 The evaluation was based on a hypothetical cohort of current heavy smokers age 60 to 64 years in Australia for the period [2002] [2003] , and it assumed a 27% reduction in screening-related mortality. We now provide an updated cost-effectiveness estimate for Australia by applying Australian costs and Australian lung cancer survival estimates to the outcomes observed in the NLST over a 10-year horizon.
Methods
We calculated the life expectancy and costs associated with three annual LDCT lung screens compared with those associated with usual care in a hypothetical scenario in which the trial population and lung cancer outcomes observed in the NLST were applied to Australian population-based survival rates with Australian cost estimates. The benefits to participants were given as expected LYs or QALYs gained, up to a 10-year time horizon from entry into screening (i.e., in relation to the NLST, at randomization). The ICER for the comparison of LDCT screening to a no-screening strategy was calculated for a base case, with sensitivity analyses for selected inputs and assumptions. Bootstrap resampling was used to determine 80% CIs for incremental costs, benefits, and ICERs for our base case (see Fig 1A) . Each bootstrap sample included a resample of all NLST participants to estimate the mean benefits and costs by screening strategy, sex, age, and smoking status. We also generated a cost-effectiveness acceptability curve, whereby the probability of costeffectiveness was plotted against the willingness-topay threshold. 14 
Data Inputs
NLST Trial Population. The NLST was a randomized trial of lung screening among people age 55 to 74 years with a smoking history of 30 or more pack-years and 15 years or less since quitting. Details of the trial protocol are reported elsewhere. 15 Briefly, 53,452 participants were randomized to receive three annual screens with either LDCT or chest radiography (August 2002-April 2004) and followed up for 5 years to December 2009. The outcomes derived from the NLST for this analysis were (1) number screened at each screening round and number with a positive screen, (2) number with lung cancer by stage and histological subtype, and (3) number of deaths due to lung cancer or other causes by the end of the study period. These outcomes were directly extracted from the NLST data set, which was obtained from the National Cancer Institute and calculated separately for each sex by smoking status (current versus former) within 5-year age strata. As in the original NLST cost-effectiveness analysis, 9 the outcomes in the chest radiography arm were assumed equivalent to a no-screening arm given that chest radiography had no effect on lung cancer mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial in the United States. 16 We reanalyzed original line data from the trial for 53,171 participants after excluding 204 participants who were deemed ineligible in the data set and 77 participants who were lost to follow-up within 1 day.
Australian Survival Rates. Lung Cancer Cases. For each participant in the NLST with a lung cancer diagnosis during the trial period (i.e., three annual screens plus 5 years of follow-up) who was still alive at the end of follow-up, beyond-trial LYs were estimated by using relative, stage-specific survival data from the New South Wales Cancer Registry (for 2005-2009), 17 which receives all notifications of primary cancer diagnoses for residents of New South Wales (NSW). We assumed that stage-specific survival rates were equivalent for LDCTscreened and unscreened cases (i.e., screening did not preferentially detect less indolent tumors). Specifically, expected LYs were given by the number of years alive within the trial study period (observed) and added to the expected beyond-trial LYs based on Australian survival probabilities by age, sex, and stage of disease. Extent of disease classification reported in the New South Wales Cancer Registry is broadly similar to that in the Surveillance, Epidemiology, and End Results summary staging system. 18 Where Surveillance, Epidemiology, and End Results summary stage was not recorded in the NLST, extent of disease was imputed by using the TNM cancer staging system as described in Supplementary Data A (Supplementary Tables 1-4) . Where multiple lung cancer diagnoses were reported for a participant (86 cases), only the first diagnosis of lung cancer was used to inform the survival estimate.
Those without Lung Cancer. For those without a lung cancer diagnosis, beyond-trial LYs were estimated from Australian life tables (2013) (2014) (2015) 19 adjusted for smoking status by using the relative risk of all-cause mortality associated with smoking in the United States, 20 as in the original NLST evaluation. For the base case, we assumed that LDCT screening had no effect on mortality from causes other than lung cancer. Specifically, we did not make assumptions regarding the number and type of potential clinically relevant incidental findings, as the required level of detailed information was not available in the NLST. We restricted the base case estimate to lung cancer outcomes and allowed for all-cause mortality benefits in sensitivity analyses. Thus, for all participants, LYs were calculated by taking observed survival in the no-screening arm (i.e., chest radiography) of the NLST and adding them to the beyond-trial Australian life expectancy calculations to derive a 10-year horizon from randomization (see Supplementary Data B for details). For the base case, we also assumed that (1) screening had no impact on beyond-trial risk of lung cancer and (2) there was no potential for radiation-induced cancer from screening, which is considered to be low in the 55 to 74 years age group. 21 Australian Costs. Year 2015 costs were used; health services perspective was taken. Any costs derived from data from earlier years were inflated by using the Australian Bureau of Statistics' weighted average of capital cities Consumer Price Index for Health series 22 and reported in Australian dollars.
The base case assumed cost for an LDCT screen was based on the existing price of the test as listed in the Medicare Benefits Schedule (AU$295 undiscounted in 2015) for a computed tomography scan of the chest. The direct medical costs involved in diagnostic follow-up for a true positive screen result or for cancer detected by usual care (no screening), staging investigations, treatment, clinician consultations, treatment interventions, and hospitalization were estimated using data from an limited, and AU$12,966 for extensive-stage SCLC undiscounted in 2005). 23 The cost of diagnostic work-up for false-positive LDCT screen results was taken from the previous Australian evaluation, which was calculated from relevant Medicare Benefits Schedule items at an average of AU$899. 41 (undiscounted in 2002) . 13 A discount rate of 5% (with sensitivity analyses from 0%-7%) was used for both costs and expected LYs, which was consistent with Australian recommendations from the beginning of the screening period. 24 The cost of lung cancer was discounted assuming it was incurred at the time of diagnosis.
Utility Weights. Quality of life was approximated by a utility, which is a measure of preference for a given health state rated on a scale where 0 equals death and 1 equals perfect health. QALYs were calculated by using the utility weights associated with screening in the NLST. 9 The baseline utilities for men and women who completed the 36-Item Short Form Health Survey were 0.76 and 0.74 respectively. We assumed a drop in utility of 0.02 at the age of 75, as observed in the U.S. National Health Measurement Study. 25 Utility weights for those with lung cancer were estimated from the same data set by TNM stage for two time periods: less than 12 months, and 12 or more months from the date of diagnosis (as was done for the NLST evaluation 9 [see Supplementary Data B]). We assumed that the utility weight assigned at 12 or more months from diagnosis continued unchanged for the remainder of the survival period.
Quality of life was not measurably affected by a positive or negative screening result in the NLST; therefore, we did not apply a screening disutility in our base case. However, to account for a potentially negative impact of positive scans on quality of life, we performed a one-way sensitivity analysis where a drop in utility occurred for 2 months after a positive screen, with a range of 0 to 0.05 (similar to the range reported in sensitivity analyses in the NLST evaluation). 9 
Sensitivity Analyses
Accounting for All-Cause Mortality. To account for the 6.7% relative reduction in all-cause mortality in the LDCT arm of the NLST, the LDCT group was assigned the observed survival in the LDCT arm and we assumed an average of 0.19 incidental findings per screenee (based on a previous report 26 ) in a sensitivity analysis. A recent study noted a wide variety of "clinically actionable" incidental findings in relation to lung screening in the Veteran's Health Administration, including emphysema and coronary artery calcifications. 27 To our knowledge there has not been a systematic costing study of incidental findings in relation to lung screening; therefore, we applied a preliminary estimate of AU$2000 per incidental finding (values between AU$0 and AU$2500 were used in the NLST 9 ), discounted such that 80% of findings occurred at the baseline scan and the remaining 20% were spread evenly over the second and third round (incidence) scans.
Variation in Cost Assumptions. One-way sensitivity analyses were conducted on a range of values for the (1) cost per screen; (2) cost of diagnostic follow-up for a false-positive result; and (3) cost of diagnosis, staging, and treatment for lung cancer. We varied the cost per screen from AU$221 (75% of the base case value) to AU$590 (double the base case value), reasoning that LDCT testing may be subject to an economy of scale if a full national screening program is implemented, making each screen cheaper, or alternatively, that the screening program may incur additional costs if multiple readings are required. The impact of varying false-positive followup costs was assessed over the range of plus or minus 20% of the base case value. The impact of varying the combined diagnosis and treatment cost was assessed by (1) assuming plus or minus 20% of the base case value for all cancer cases and (2) increasing the cost of stage III/IV NSCLC cases by 100% to explore the potential for increased costs associated with newer targeted therapies and mutation testing.
Survival weighted by the demographic profile of the QLCSS. The screening outcomes from the NLST were compared with those from an Australian feasibility study of lung screening that replicated the NLST protocol for the LDCT arm (the Queensland Lung Cancer Screening Study [QLCSS] , 2007-2014). 28, 29 Specifically, participants age 60 to 74 years were recruited through advertisements and a media press release. 28 After excluding those younger than 60 years at randomization, we calculated the estimated LYs in Australia by weighting the LYs of individuals in the NLST according to the proportion of QLCSS participants within each 5-year age group, sex, and smoking status strata.
Variation in the Estimated Time Horizon. A one-way sensitivity analysis examined a lifetime horizon as compared with the 10-year base case calculation for LYs.
Variation in Nodule Management and Definition of a Positive Scan. In the NLST, any LDCT-detected nodule that was larger than 4 mm was considered a positive scan, and the false-positive rate (FPR) was 24%. Attempts at reducing the FPR have come from more recent nodule management protocols such as the British Thoracic Society guidelines and Lung-RADS (an FPR of 13% with use of the NLST data). 30, 31 Adopting this definition would change the positive predictive value (proportion of criteria-positive participants with cancer) of a screening program. Thus, we performed a one-way analysis of varying the number of false-positive LDCT outcomes following the incidence scans equivalent to a range of plus or minus 20% of the observed positive predictive value.
Restrict the Definition of Screening Eligibility. We evaluated current and past smokers separately, in addition to evaluating an eligibility criterion of a 40-pack-year smoking history as an alternative to the 30-pack-year NLST criterion (as in previous studies). [32] [33] [34] 
Results
The number of lung cancers and lung cancer deaths observed in the NLST are reproduced in Supplementary Data A (see Supplementary Table 4 ). Overall, there were 934 NSCLCs and 142 SCLCs in the LDCT arm and 802 NSCLCs and 161 SCLCs in the no-screening arm. There were 214 more localized NSCLCs diagnosed in the LDCT arm than in the no-screening arm, comparable numbers diagnosed at the regional disease stage, and 87 fewer distant disease cases. The proportions of SCLC by stage of disease at diagnosis were almost identical across the two arms.
The mean LYs and QALYs were greater in the LDCT arm than in the no-screening arm, both within the trial (observed) and at the 10-year time horizon (Table 1) . The incremental expected LYs saved of LDCT-screened individuals with a lung cancer diagnosis was 0.54 years over the 10-year period with use of the Australian lung cancer survival rates (compared with the 1.6-year incremental benefit over a lifetime that was reported in the NLST evaluation 9 ). In the base case, the average cost per person was higher in the LDCT scenario than in the no-screening scenario, primarily because of the cost of the screen itself and the diagnostic work-up of positive results (Table 2) (Table 3 ). The corresponding ICERs were AU$138,000 (80% CI: AU$84,700-AU$353,000) per LY gained and AU$233,000 (80% CI: AU$128,000-AU$1,110,000) per QALY gained. The ICERs by current and former smoking status were AU$123,000 and AU$1,480,000 per QALY gained, respectively. The costeffectiveness acceptability curve is shown in Figure 1B , where the probability of a cost-effective screening scenario increases as the willingness-to-pay threshold (horizontal axis) increases, approaching a 98.4% probability of cost-effectiveness (but this only occurs at extremely high thresholds of >AU$500,000/QALY gained). A threshold analysis for the cost of an LDCT screen demonstrated that even at very low screening costs, lung screening would not be cost-effective under the base case assumptions tested here (Fig. 1B) .
Sensitivity Analyses
The variation in base case parameters resulted in ICER estimations that varied from AU$127,000 to a Observed outcomes for the no-screening scenario were derived from the chest radiography arm of the NLST but assumed to be equivalent to a noscreening arm given that chest radiography had no effect on lung cancer mortality as a screening intervention in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. AU$509,000 per QALY gained and is presented in Table 4 and Figure 2 . The largest ICER was due to the degree of disutility assigned to a false-positive screen result. Specifically, in the worst case, where a disutility of 0.05 was assigned to the 2 months after a false-positive scan result, the ICER was AU$509,000 per QALY gained. The smallest (most favorable) ICER was observed when all-cause mortality was factored into the survival benefit. Specifically, including the mortality benefit observed in the LDCT arm from causes other than lung cancer resulted in an ICER of AU$127,000 per QALY gained. When the cost of incidental findings (estimated at AU$2000 per finding) was also included in the calculation, the ICER increased to AU$157,000 per QALY gained. Of the main input costs assessed, the cost per screen had the greatest impact on the ICER, which ranged from AU$204,000 to AU$351,000 per QALY gained, followed by the cost of following up false-positive results (AU$211,000-AU$256,000 per QALY gained). Varying the mean cost of treatment by plus or minus 20% had a very minimal impact on the ICER. Increasing the cost of stage III/IV lung cancers by 100% resulted in a slightly more favorable ICER (AU$223,000/QALY gained) than the base case.
The impact of the time horizon for survival benefit was tested in the range of 10 years up to a lifetime, with the resulting incremental LYs shown in Figure 3 . The value of additional LYs (and QALYs) gained by LDCT screening increases as the horizon approaches approximately 14 years, toward a maximum of 0.0127 LYs (0.0075 QALYs), with a corresponding ICER of AU$210,000 per QALY gained. When the horizon was extended further than 14 years, the incremental LYs gained by screening decreased toward a minimum of 0.0096 LYs (0.0049 QALYs) at the lifetime horizon, with a corresponding ICER of AU$319,000 per QALY gained.
Varying the discount rate from 0% to 7% changed the ICER from AU$212,000 to AU$262,000 per QALY gained over the 10-year time horizon. Changing the expected number of false-positive results in incidence scans to reflect potential differences in positive predictive value (PPV), also resulted in a relatively small change in ICER. The observed PPV for incidence screens in the trial was 5.9%. A 20% decrease in PPV resulted in an incremental cost per person in the LDCT group of AU$1659, corresponding to a 6% increase in the additional cost of LDCT per person. A 20% increase in PPV resulted in an approximately 4% decrease in the additional cost per person.
Differences in the distribution of participants in the NLST compared with those in the QLCSS by age, sex, and smoking status are presented in Supplementary Table 5 . Lung cancer incidence in the QLCSS was similar to that in the same age range in the LDCT arm of the NLST (121 [95% CI: 66-202 versus 85 cases per 10,000 personyears, respectively]). Weighting the results by the demographic profile of QLCSS participants decreased the ICER to AU$154,000 per QALY gained. The reduction in ICER from that of the base case was mostly due to the exclusion of people younger than 60 years at randomization. 
Discussion
By applying Australian cost and population-based survival data to the NLST outcomes, we estimated that lung cancer screening with LDCT would cost AU$233,000/QALY gained and AU$138,000/LY gained over a 10-year time horizon. Our base case estimates were higher than the previous Australian estimate of AU$105,090 per QALY gained in 2002. 13 This is not surprising given the wide range of ICERs that we observed in the sensitivity analyses, and it illustrates the importance of model parameters and assumptions. For example, the previous Australian estimate was based on a hypothetical cohort of current smokers and the estimated ICER was more similar to the ICER for current smokers in our analysis (i.e., AU$123,000/ QALY gained). However, even the lower ICER estimates in our study were more than double what would indicatively be considered cost-effective in the Australian context (i.e., the current indicative willingness-to-pay threshold is approximately AU$30,000-AU$50,000/QALY gained). 35 The NLST reported a statistically significant 6.7% (95% CI: 1.2-13.6) mortality benefit of LDCT screening on deaths from any cause (3.2% was due to deaths other than lung cancer). 2 This result suggests that lung screening may capture clinically significant abnormalities other than lung cancer that are detected during the screening examination (e.g., heart, abdomen). One study reported that "actionable" conditions such as coronary artery calcification or emphysema occurred in 19% of individuals undergoing LDCT lung screens, including "severe" findings that merited immediate attention in 0.8% of cases. 26 Given the smoking history of those eligible for lung screening, it is not surprising that incidental findings are common. We applied the rate of 19% actionable incidental findings per LDCT participant in a sensitivity analysis, at a cost of AU$2000 per finding. When we combined these (most likely conservative) costs with the other-cause mortality benefit, the ICER of LDCT was more favorable than the base case. Thus, including non-lung cancer survival benefits in cost-effectiveness evaluations might improve ICERs, although the potential for overtreatment and complications in relation to these conditions would also need consideration. We also did not factor in a smoking cessation intervention, which would increase the cost of a screening program but might reduce morbidity and the long-term health costs of smoking, thereby improving cost-effectiveness. 33, 36 Two recent systematic reviews of cost-effectiveness evaluations of LDCT screening have highlighted the fact that many factors affect ICER estimates and demonstrated the difficulties inherent in comparing ICERs across evaluations with different underlying assumptions. 10, 11 Although not directly comparable, our base case ICER is higher than that reported for the original NLST evaluation ($81,000/QALY gained 9 ). This is due to differences in the model assumptions, health system costs, value of the dollar, and survival rates across the two populations. The reviews also reported that ICERs for LDCT lung screening were highly sensitive to aspects of screening program design and implementation, including the definition of the target screening group, the cost of an LDCT screen, and the proportion of lung cancers detected at an early stage. 10, 11 Our analysis was consistent with these findings. For example, varying the cost of an LDCT scan had a large impact on our ICER estimates. The cost of a screen could potentially be reduced if trained radiographers were utilized in conjunction with experienced thoracic radiologists 37 or in conjunction with an accurate computerized vision tool (computer-aided detection). 38 As found in previous reports, this highlights the importance of factors affecting the number of screens within a program (e.g., the optimal screening interval and the definition of screening results requiring follow-up scans). 32, 34 One of the biggest factors affecting both the number of scans and cost-effectiveness of lung screening is the criteria used for screening eligibility.
The eligibility criteria for the NLST was age (55-74 years) and smoking history (30 pack-years and <15 years since quitting), and almost all trials to date have used some variation of these criteria. Although mostly underpowered, trials utilizing less conservative eligibility criteria (e.g., 20 pack-years) have not replicated the lung cancer mortality benefit demonstrated in the NLST. 39, 40 Restricting eligibility criteria to individuals with a smoking history of 40 or more pack-years or to current smokers alone improved cost-effectiveness in our sensitivity analyses, resulting in findings which are similar to those presented elsewhere. 32, 33, 41 However, data demonstrating that the balance of harm, benefits, and costs can be optimized with the use of lung cancer risk prediction tools are mounting. 42, 43 These tools are now being incorporated into trial eligibility criteria [44] [45] [46] and are expected to improve screening effectiveness.
The recommended age range for lung screening is also critical in terms of the risk of radiation-induced lung cancer. For younger age groups (<50 years) or those with a lower risk of lung cancer, the radiation risks are likely to outweigh the benefit of screening, especially for women. 21 In the NLST, it was predicted that approximately one cancer death may be caused by radiation from imaging per 2500 people screened. On the basis of these estimates, the benefit in preventing lung cancer deaths in the NLST is greater than the radiation risk, which may present 10 to 20 years later. We did not account for radiation-induced cancers, given that the typical lag between radiation exposure and cancer diagnosis is one to two decades or more. 47 Thus, leaving out radiationinduced cancers altogether was not likely to substantially affect our results. In the NLST it was estimated that ICERs were only slightly less favorable over an estimated range of radiation-induced lung cancer deaths. 9 We demonstrated that the ICER was particularly sensitive to the degree of disutility assigned to the short-term psychological impact of screening results. Indeed, the highest ICER that we observed in sensitivity analyses was when a 2-month disutility weighting for false-positive scan results was included, resulting in an ICER of AU$509,000/QALY gained. In the NLST no loss in utility was detected by the 36-Item Short Form Health Survey after a false-positive screen result, which was potentially explained by noting that the information regarding the frequency and clinical significance of false-positive results before study entry may have prevented distress. 9 In the NELSON trial, scores on the 12-Item Short Form Health Survey similarly did not show any clinically relevant changes across the trial; however, the Impact of Event Scale (measuring lung cancer-specific distress) detected significant differences 2 months after a screening result.
48
That is, participants with an indeterminate result requiring 3 months' surveillance responded with higher distress scores compared with baseline. Both the number and management of false-positive results appear to be critical factors for cost-effectiveness; however, very few data on utilities in LDCT lung screening and for lung cancer management have been published. 49 Thus, psychological and health-related quality of life in relation to both screening and lung cancer management represent a significant evidence gap, especially in the Australian context. Furthermore, the quality of the screening information given to participants and risk communication are critical to reducing distress, thereby improving cost-effectiveness.
In addition to the potential for psychological harm in relation to false-positive screen results, the ICER is also sensitive to costs involved in following up false-positive scan results. The number and cost of false-positive screen results depends on the definition of a positive scan and the nodule management strategy used. The proportion of positive results (both false-positive and true-positive results) has been shown to vary with the age of the cohort and the number of screens. 33, 34 In the NLST, more than 20% of LDCT participants required follow-up after their first screen, and in approximately 25% of surgical procedures, the nodule was determined to be benign. 2 Since the NLST, there have been advances in nodule management strategies that have aimed to reduce the number of false-positive results in a screening program. 31 In our sensitivity analyses, varying the cost of false-positive follow-up result had a greater impact on the ICER than did varying the cost of lung cancer treatment itself. To date, there is no consensus on the definition of a screen-detected suspicious nodule or on the management of potentially malignant screen-detected nodules. However, research on using nodule risk calculators to optimize sensitivity and specificity in this domain is under way. 44 The cost of lung cancer treatment that was used in our analysis came from a hospital-based costing study conducted in [2005] [2006] [2007] [2008] . 23 These costs did not include routine blood tests, hospital department infrastructure, staff, or out-of-hospital costs such as general practitioner or community-based care costs. The main cost components were due to hospitalization and chemotherapy, and only two patients were treated with tyrosine kinase inhibitors. 23 New lung cancer therapies continue to be added to the Australian pharmaceutical benefits scheme (i.e., all government-subsidized medicines), such as those that target EGFR mutation and anaplastic lymphoma kinase mutation-positive NSCLC and immune check point inhibitors. These new therapies can be expensive, and uptake of these drugs and related technologies is increasing. 50 Although the cost of these therapies was not captured in our base case, increasing the cost of stage III/IV lung cancers by 100% resulted in a slightly more favorable ICER (AU$223,000/QALY gained). As the use of these therapies becomes a part of routine care, the benefits of early detection will increase.
An important limitation of our study is the use of population-based rates of lung cancer survival to estimate benefits to participants. The survival rates taken from the NSW population included lung cancer survival among lowrisk smokers and never-smokers (w15%). Further, population-based survival rates do not account for a potential screening-related survival benefit related to factors such as screen detected indolent or minimally invasive disease. Given these considerations, the LY calculations in our analysis may be overestimated for non-screen-detected cases given that this is a sample of heavy smokers, yet be underestimated in screen-detected cases given the potential for a screening-related survival benefit.
Estimates of the cost-effectiveness of lung screening are highly sensitive to the proportion of cancers detected at an early stage, 10 and our ICER estimates are contingent on the number of lung cancers detected in the NLST. Our estimates may therefore differ somewhat from what might be observed for a population-based screening scenario. This is because the distribution of disease and the types of people who are likely to present themselves for a population-based screening program are potentially different from that of a trial scenario. Indeed, QLCSS participants were not representative of the Australian population, with a higher proportion of the participants having tertiary education. 29 In Australia, participation in existing population-based cancer screening programs is known to be lower among subgroups with a high prevalence of smoking, such as those living in lower socioeconomic areas (e.g., see the 2017 Australian Institute of Health and Welfare National Bowel Cancer Screening Program monitoring report 51 
)
Engaging subgroups of the population with high smoking rates (the "hard to reach") in lung screening is likely to be a challenge in Australia and will be an important factor for optimizing the proportion of cancer detected at an early stage. We did not include any recruitment or program costs that would be needed for an equitable population-based program in which referral to screening would need to be embedded in the health system.
Although this analysis has found that lung cancer screening based on the NLST protocol is not yet likely to be cost-effective in Australia, investment in reducing the lung cancer burden in Australia remains an imperative. Total expenditure on lung cancer grew by 33% from 2000-2001 to 2004-2005 , and this increase was higher than the increase in the expenditure for all cancers (31%) and all diseases (20%). 52 Primary prevention through tobacco control is likely to be the most effective and cost-effective long-term strategy for reducing the burden of lung cancer. However, given the 20-to 30-year lag between tobacco exposure and lung cancer incidence, the full benefits of these interventions will not be realized for many years to come, and there is room for secondary prevention to have a significant impact.
Given that significant reductions in lung cancer mortality can be achieved with LDCT screening, it is important that future economic evaluations consider alternative screening eligibility criteria, intervals, nodule management, the impact and costs of new therapies, investigations of incidental findings, and incorporation of smoking cessation interventions. There is also a need for more systematic data on the identification and treatment of incidental findings, the impact of screening on psychological well-being, and the potentially mitigating effects of effective risk communication. Reducing uncertainty in these areas will allow for more reliable and possibly more favorable cost-effectiveness estimates for Australia.
